All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Lurbinectedin/Atezolizumab Combination Improves Survival in ES-SCLC

October 15th 2024

Lurbinectedin plus atezolizumab produced significant OS and PFS benefits as frontline maintenance for extensive-stage small cell lung cancer.

TROP2 Offers Attractive Therapeutic Target in Breast Cancer and Other Solid Tumors

October 15th 2024

Ian Krop, MD, PhD, and Aditya Bardia, MD, MPH, FASCO, detail how TROP2-directed ADCs have generated excitement in breast cancer and other solid tumors.

Increased ctDNA and MMR Testing May Alter Adjuvant and Neoadjuvant CRC Management

October 15th 2024

Benjamin Adam Weinberg, MD, discusses the prognostic value of adjuvant ctDNA testing in CRC and the role of immune checkpoint inhibition in dMMR CRC.

Prospective Trials Could Refine Potential Roles for Radiation in Advanced RCC

October 15th 2024

Chad Tang, MD, discusses how radiation could play a role in advanced renal cell carcinoma.

NKT2152 Generates Responses in Heavily Pretreated Advanced ccRCC

October 14th 2024

NKT2152, a novel HIF2α inhibitor, produced responses in heavily pretreated advanced clear cell renal cell carcinoma.

Selinexor Paves the Way for More Affordable, Effective Treatment Options in Myelofibrosis

October 14th 2024

Joseph M. Scandura, MD, PhD, discusses the importance of research with single-agent selinexor in JAK inhibitor–naive myelofibrosis.

BTK Inhibitors vs Venetoclax: Considerations for Frontline Treatment Selection in CLL

October 14th 2024

Nitin Jain, MD, discusses the use of BTK inhibitor– and venetoclax-based regimens for the frontline treatment of chronic lymphocytic leukemia.

Dana-Farber Cancer Institute Delivers ‘Simple Immediate Impact’ to Patient Comfort Using Weighted Blankets

October 14th 2024

Dana-Farber Cancer Institute has used weighted blankets to aid in patient care.

EU Approval Sought for Darolutamide Plus ADT for mHSPC

October 14th 2024

The EMA has received a submission seeking the approval of darolutamide in combination with ADT in metastatic hormone-sensitive prostate cancer.

Sunvozertinib Receives Breakthrough Therapy Designation for Treatment-Naive EGFR Exon 20+ NSCLC in China

October 14th 2024

China’s CDE has granted breakthrough therapy designation to first-line sunvozertinib for EGFR exon 20 insertion mutation–positive NSCLC.

Chemoimmunotherapy Is at the Forefront of the Perioperative NSCLC Paradigm

October 14th 2024

Combination therapies with neoadjuvant ICIs and chemotherapy followed by an adjuvant ICI are here to stay in resectable non–small cell lung cancer.

Empowering Breast Surgeons: A Call for Collective Action

October 14th 2024

As survival rates continue to rise for patients with breast cancer, innovations are still needed to advance surgical care for these patients.

Meta-Analysis Shows Efficacy, Safety of CAR T-Cell Therapy in R/R Mantle Cell Lymphoma

October 14th 2024

CAR T-cell therapy demonstrated efficacy and manageable safety in mantle cell lymphoma in a systematic review of prospective and real-world studies.

Assay Predicts Response to Neoadjuvant Atezolizumab Plus Chemotherapy in TNBC

October 13th 2024

The DetermaIO gene expression test was predictive of responses to neoadjuvant atezolizumab plus chemotherapy in early-stage triple-negative breast cancer.

The OncFive: Top Oncology Articles for the Week of 10/6

October 12th 2024

Inavolisib triplet wins FDA approval in PIK3CA+ breast cancer, perioperative pembrolizumab improves EFS in head and neck cancer, and more from OncLive this week.

Fixed-Duration Ibrutinib/Venetoclax Elicits Meaningful Survival Benefit in High-Risk CLL/SLL

October 12th 2024

Fixed-duration ibrutinib plus venetoclax generated meaningful survival benefits and durable responses in high-risk subgroups of patients with CLL/SLL.

FDA Approves Single-Dose, Intravenous Paclitaxel Biosimilar for Breast Cancer

October 11th 2024

A single-dose formulation of paclitaxel for injectable suspension has been launched in the United States for metastatic breast cancer.

Cisplatin’s Prevalence in Bladder Cancer Falters With the Introduction of Enfortumab Vedotin

October 11th 2024

Jacqueline Brown, MD, explains the need to determine optimal second-line bladder cancer treatments for use after enfortumab vedotin/pembrolizumab.

FDA Grants Orphan Drug Designation to LMP744 for Glioma

October 11th 2024

LMP744 has been granted orphan drug designation by the FDA for the treatment of patients with glioma.

EU Green Lights CLDN18 RxDx Assay As Companion Diagnostic for Zolbetuximab in Gastric Cancer

October 11th 2024

CE certification was granted to the VENTANA CDLN18 RxDx assay for the assessment of CLDN18 protein expression in gastric or GEJ adenocarcinoma in Europe.